arrow
P

Pamela Pizzutilo

irccs istituto tumori bari giovanni paolo ii
H指数:19
被引数:1,218

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
CIRCULATING AND MOLECULAR MARKERS OF INFLAMMATION: IMPACT ON TREATMENT RESPONSE AND SURVIVAL AMONG OLDER PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS
2022-11-070
OA
EFFICACY AND TOXICITY OF SINGLE AGENT IMMUNE CHECKPOINT INHIBITORS AMONG ADULTS WITH CANCER AGED ≥80 YEARS: A MULTICENTER INTERNATIONAL COHORT STUDY
2021-11-100
OA
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021-04-0144
OAAI
Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller
2021-03-0118
PREAI
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

在PD-L1表达 ≥ 50% 的NSCLC患者的大型真实队列中,派姆单抗的免疫相关不良事件及其与临床结局的关系

2020-11-0163
OAAI
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
2020-10-1958
OAAI
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
2020-09-2524
PREAI
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation

DiM: 晚期非小细胞肺癌二线或进一步免疫治疗的预后评分: 一项外部验证

2020-09-017
OAAI
Smoking Prevalence, Knowledge and Perceptions on Tobacco Control Among Healthcare Professionals: A Survey in an Italian Cancer Center
2020-08-135
PREAI